The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Rasmus Strøm Risbjerg; Mie Vennize Hansen; Anne Sofie Sørensen; Tue Wenzel Kragstrup

doi:10.1186/s40164-020-00167-1

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, Tue Wenzel Kragstrup^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Kommentar/debat/letter to the editor › Forskning › peer review

9 Citationer (Scopus)

Abstract

This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production. This treatment strategy is used in several immune mediated inflammatory diseases such as rheumatoid arthritis and small vessel vasculitis. The immune related adverse events associated with immune checkpoint inhibition resemble immune mediated inflammatory diseases. Here, we report a lower incidence of hypothyroidism in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. This letter aims to increase awareness of the immune related adverse events associated with immune checkpoint inhibition in future clinical trials of immune checkpoint inhibition together with B cell depletion (primarily trials of B cell lymphomas). Hopefully, observations from these clinical trials can guide future treatment strategies to treat or prevent immune related adverse events associated with immune checkpoint inhibition.

Originalsprog	Engelsk
Artikelnummer	9
Tidsskrift	Experimental Hematology and Oncology
Vol/bind	9
DOI	https://doi.org/10.1186/s40164-020-00167-1
Status	Udgivet - maj 2020

Adgang til dokumentet

10.1186/s40164-020-00167-1Licens: CC BY

Andre filer og links

http://www.scopus.com/inward/record.url?scp=85085372794&partnerID=8YFLogxK

Citationsformater

@article{a87266ffe44f4e7ea94d1ee7332464bb,

title = "The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition",

abstract = "This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production. This treatment strategy is used in several immune mediated inflammatory diseases such as rheumatoid arthritis and small vessel vasculitis. The immune related adverse events associated with immune checkpoint inhibition resemble immune mediated inflammatory diseases. Here, we report a lower incidence of hypothyroidism in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. This letter aims to increase awareness of the immune related adverse events associated with immune checkpoint inhibition in future clinical trials of immune checkpoint inhibition together with B cell depletion (primarily trials of B cell lymphomas). Hopefully, observations from these clinical trials can guide future treatment strategies to treat or prevent immune related adverse events associated with immune checkpoint inhibition.",

keywords = "B cell depletion, Hypothyroidism, Immune checkpoint inhibition, Immune mediated inflammatory disease, Immune related adverse events",

author = "Risbjerg, {Rasmus Str{\o}m} and Hansen, {Mie Vennize} and S{\o}rensen, {Anne Sofie} and Kragstrup, {Tue Wenzel}",

year = "2020",

month = may,

doi = "10.1186/s40164-020-00167-1",

language = "English",

volume = "9",

journal = "Experimental Hematology and Oncology",

issn = "2162-3619",

publisher = "BioMed Central Ltd.",

}

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. / Risbjerg, Rasmus Strøm; Hansen, Mie Vennize; Sørensen, Anne Sofie et al.
I: Experimental Hematology and Oncology, Bind 9, 9, 05.2020.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Kommentar/debat/letter to the editor › Forskning › peer review

TY - JOUR

T1 - The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

AU - Risbjerg, Rasmus Strøm

AU - Hansen, Mie Vennize

AU - Sørensen, Anne Sofie

AU - Kragstrup, Tue Wenzel

PY - 2020/5

Y1 - 2020/5

N2 - This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production. This treatment strategy is used in several immune mediated inflammatory diseases such as rheumatoid arthritis and small vessel vasculitis. The immune related adverse events associated with immune checkpoint inhibition resemble immune mediated inflammatory diseases. Here, we report a lower incidence of hypothyroidism in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. This letter aims to increase awareness of the immune related adverse events associated with immune checkpoint inhibition in future clinical trials of immune checkpoint inhibition together with B cell depletion (primarily trials of B cell lymphomas). Hopefully, observations from these clinical trials can guide future treatment strategies to treat or prevent immune related adverse events associated with immune checkpoint inhibition.

AB - This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production. This treatment strategy is used in several immune mediated inflammatory diseases such as rheumatoid arthritis and small vessel vasculitis. The immune related adverse events associated with immune checkpoint inhibition resemble immune mediated inflammatory diseases. Here, we report a lower incidence of hypothyroidism in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. This letter aims to increase awareness of the immune related adverse events associated with immune checkpoint inhibition in future clinical trials of immune checkpoint inhibition together with B cell depletion (primarily trials of B cell lymphomas). Hopefully, observations from these clinical trials can guide future treatment strategies to treat or prevent immune related adverse events associated with immune checkpoint inhibition.

KW - B cell depletion

KW - Hypothyroidism

KW - Immune checkpoint inhibition

KW - Immune mediated inflammatory disease

KW - Immune related adverse events

UR - http://www.scopus.com/inward/record.url?scp=85085372794&partnerID=8YFLogxK

U2 - 10.1186/s40164-020-00167-1

DO - 10.1186/s40164-020-00167-1

M3 - Comment/debate/letter to the editor

C2 - 32509417

AN - SCOPUS:85085372794

SN - 2162-3619

VL - 9

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

M1 - 9

ER -

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater